Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Regimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens.Observational.We first calculated RATE-sparing options available to an ave...

Full description

Bibliographic Details
Main Authors:	Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4072535?pdf=render

Similar Items

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
by: Graeme J Moyle, et al.
Published: (2015-01-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01)

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
by: Rashmee Patil, et al.
Published: (2015-01-01)

Approaches to tenofovir and abacavir drug shortages in South Africa: A guide for clinicians
by: Laurie Schowalter, et al.
Published: (2012-06-01)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
by: Rahaba Marima, et al.
Published: (2020-08-01)

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

Cardiovascular side effects of the antiretroviral agents rilpivirine, efavirenz, etravirine and abacavir : possible underlying mechanisms
by: Bergin, Hild
Published: (2014)

Selenium abrogates tenofovir/lamivudine/efavirenz-induced hepatotoxicity in rats
by: Elias Adikwu, et al.
Published: (2021-01-01)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
by: Langdahl Bente L, et al.
Published: (2011-10-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

ANTIRETROVIRAL DRUGS EFAVIRENZ AND TENOFOVIR AND THEIR EFFECTS ON ARTERIAL REMODELING AND PROTEASE ACTIVITY
by: Roberts, Ladeidra Monet
Published: (2015)

Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir
by: Tormo Consuelo, et al.
Published: (2011-02-01)

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
by: Kunchok Dorjee, et al.
Published: (2021-09-01)

Safety of atazanavir/ritonavir with tenofovir disoproxil fumarate in HIV-infected adolescents
by: T. Bunupuradah, et al.
Published: (2014-04-01)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)<sub>2 </sub>vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
by: Focà Emanuele, et al.
Published: (2012-02-01)

Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC
by: Arun Ramaswamy, et al.
Published: (2018-02-01)

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
by: Pobiner Bonnie F, et al.
Published: (2005-04-01)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
by: Squires KE, et al.
Published: (2017-03-01)

Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir
by: Chenai Sheilla Mutiti, et al.
Published: (2021-05-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Dyslipidaemia associated with the highly active antiretroviral therapy in aids patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir)
by: Hamilton Domingos, et al.

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
by: Mohammed Lamorde, et al.
Published: (2012-01-01)

Safety and Efficacy of Fixed Drug Combination Tenofovir, Lamivudine and Efavirenz to Prevent Transmission of HIV
by: Pramendra Sirohi, et al.
Published: (2021-07-01)

Gradient high performance liquid chromatographic method for the simultaneous analysis of efavirenz, emtricitabine and tenofovir
by: Koekemoer, Sonya Mariana
Published: (2016)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
by: Tasker Sybil, et al.
Published: (2009-06-01)

Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
by: Thomas A Rasmussen, et al.
Published: (2012-01-01)

Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis
by: Melanie R. Nicol, et al.
Published: (2019-09-01)

Avaliação da Interação dos Antirretrovirais Lamivudina, Efavirenz e Tenofovir e seus excipientes
by: Elionai Cassiana de Lima Gomes
Published: (2015)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz
by: Yonatan Oster, et al.
Published: (2020-12-01)

Cellular mechanisms underlying the cardiovascular toxicity of the highly active anti-retroviral therapy Atripla : efavirenz, emtricitabine and tenofovir
by: Faltz, Mary
Published: (2013)

Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
by: Takeshi Nishijima, et al.
Published: (2012-01-01)

Abacavir-induced liver toxicity
by: Maria Diletta Pezzani, et al.
Published: (2016-09-01)

Abacavir: it’s use and hypersensitivity
by: Helena Rabie, et al.
Published: (2009-12-01)

Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria
by: Sikiru Olatunji Usman, et al.
Published: (2020-11-01)

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity <it>in vitro</it>: a mechanism of action study
by: Svarovskaia Evguenia S, et al.
Published: (2009-05-01)

Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China
by: Ya-Song Wu, et al.
Published: (2016-01-01)